All In Biotech

Drug Trial Radar · NCT07678775

Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants With Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)

Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

107

Planned (sponsor's estimate)

Start

Jun 5, 2026

Primary completion

Oct 2030

Study completion Oct 2030

Sponsor

Lead sponsor
ML Bio Solutions, Inc.Industry
Sponsor type
Industry
First posted
Jul 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label extension (rollover) study designed to evaluate the long-term safety and efficacy of BBP-418 (ribitol) in participants with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) who have previously participated in Study MLB-01-005 (Fortify). Participants will receive BBP-418 administered orally at protocol-defined doses and schedules. The study will assess long-term safety through monitoring of adverse events, clinical laboratory evaluations, and other safety assessments. Efficacy will be evaluated using functional measures and other clinical endpoints relevant to LGMD2I/R9. Participants will be followed for up to 36 months, with a final safety follow-up assessment conducted approximately 30 days after the last dose of study drug.

Conditions

  • Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)

Interventions

  • BBP-418 (ribitol)Drug

    Drug: BBP-418. Single arm. Participants who completed Study MLB-01-005 and meet eligibility criteria will receive BBP-418 (ribitol) taken orally twice daily at 9 or 12g (based on body weight measured) for up to 36 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of treatment-emergent adverse events to assess long-term safety of BBP-418.Time frame: 36 months
  2. Change from baseline in North Star Assessment for LGMD2I/R9 to assess long-term efficacy of BBP-418.Time frame: 36 months

Locations

20 sites in 8 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • University of California Irvine Medical Center

    Orange, California

  • University of Colorado Hospital (UCH) - Anschutz Medical Campus

    Aurora, Colorado

  • University of Florida Health Center for Pediatric Neuromuscular and Rare Diseases

    Gainesville, Florida

  • University of Iowa Stead Family Children's Hospital

    Iowa City, Iowa

  • University of Kansas Medical Center (KUMC)

    Kansas City, Kansas

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • University of Minnesota Medical School

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Children's Hospital of the Kings Daughters

    Norfolk, Virginia

  • Royal Brisbane and Women's Hospital

    Brisbane, Australia

  • Rigshospitalet, Neuromuscular Clinic and Research Unit

    Copenhagen, Denmark

  • Charité Universitätsmedizin Berlin and Max Delbrück Center

    Berlin, Germany

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • Universitetssykehuset Nord-Norge, Department of Neurology

    Tromsø, Norway

  • UCL Great Ormond Street Hospital

    London, United Kingdom

  • Newcastle University - John Walton Muscular Dystrophy Research Centre

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.